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Sensitive detection of eBV 
microRnAs across cancer spectrum 
reveals association with decreased 
survival in adult acute myelocytic 
leukemia
Mercedeh Movassagh1, Cliff oduor2,3, catherine forconi4, Ann M. Moormann4 & 
Jeffrey A. Bailey  1,5*
epstein Barr virus (eBV) is the etiologic agent involved in numerous human cancers. After infecting 
the host, eBV establishes a latent infection, with low levels of messenger RnA (mRnA) and protein 
expression, evolved to evade immune recognition. conversely, eBV microRnAs (miRnA) are expressed 
ubiquitously and abundantly within infected cells. their role in tumor biology and clinical outcomes 
across the spectrum of cancer is not fully explained. Here, we applied our bioinformatics pipeline for 
quantitative EBV miRNA detection to examine sequencing data of 8,955 individual tumor samples 
across 27 tumor types representing the breadth of cancer. We uncover an association of intermediate 
levels of viral miRnA with decreased survival in adult acute myeloid leukemia (AML) patients 
(p = 0.00013). Prognostic modeling of this association suggests that increased EBV miRNA levels 
represent an independent risk factor for poor patient outcomes. Furthermore, we explore differences 
in expression between elevated and absent viral miRNA loads in adult AML tumors finding that EBV 
positivity was associated with proinflammatory signals. Together, given no associations were found for 
pediatric AML, our analyses suggests eBV positivity has the potential for being a prognostic biomarker 
and might represent a surrogate measure related to immune impairment in adult patients.
Epstein Barr virus (EBV) is linked to 1.5% of all human cancers across the world1 based on known viral-containing 
malignancies such as Burkitt Lymphoma (BL), nasopharyngeal carcinoma (NPC), stomach cancer, and diffuse 
large B cell lymphoma (DLBCL). EBV appears integral to oncogenesis and virus containing tumors have been 
associated with distinct patterns of tumor mutations supporting the role of EBV as an oncogenic driver2,3. The 
full extent of EBV’s influence has been difficult to determine using genomics, and classification remains largely 
based on Epstein Barr virus encoded small RNAs (EBERs) staining of tumor samples4. Systematic genomic study 
of EBV and its effects on cancer prognosis through genome and transcriptome sequencing has been limited due 
to lack of sensitive and consistent detection methods5.
Investigations are also complicated by the chronicity of EBV infection. Following primary infection in an 
immune competent individual, EBV is controlled, and becomes a lifelong chronic infection. It lies latent inside a 
small percentage (1–10 cells per million) of host B cells, as well as possibly a subset of epithelial cells, with min-
imal protein translation, thereby escaping immune surveillance by the human host (reviewed in6). EBV persis-
tence has been associated with a variety of host immune evasion strategies, including inhibition of immune cell 
function, dampening of apoptotic pathways, and interfering with antigen processing pathways. Moreover, since 
the virus has established a life-long persistence in 97% of adults globally, low levels of detectable virus in cancer 
do not necessarily imply infected tumor cells but might simply represent detection of a normal chronic infection7.
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However, the virus may impact the microenvironment around infected cells and thus have the potential to 
influence the tumor without directly infecting malignant cells8. Also, the ability to control the virus and EBV reac-
tivation may serve indirectly as a surrogate of general host immune competence. An example of such interplay 
is the inflammatory effects of EBV on gastric cancers through pro-inflammatory molecule expression such as 
cytokines responsible for increase in growth in EBV infected cells (IL5,IL6)9. Hence, EBV infection and its control 
has the potential to give insight into both tumor biology and host immunity.
To date, genomic and molecular studies across the breadth of cancer have been limited in their inclusion 
of viral content. While EBV has been observed by EBERs detection in tumors not traditionally thought to be 
infected, such as head and neck, lung, ovarian, colon, and esophageal cancer, these cancers have not been rou-
tinely screened for EBV10. There have also been reports of EBV positive tumors which lack significant EBERs 
expression4. While more data rich, genomic studies have focused on viral messenger RNA (mRNA) transcrip-
tome evaluation, such studies are limited by the low levels of viral mRNA expression and have focused on further 
understanding the role of EBV in cancer cell biology. In addition, these were mainly limited to studying clas-
sic cases of EBV-associated malignancies, such as BL and NPC2,11. Other genomic studies are also confounded, 
including exome sequencing since probes for EBV capture are not routinely included limiting the ability of sec-
ondary analysis across a wide breadth of cancer.
Unlike viral messenger RNAs (mRNA), EBV microRNAs (miRNAs) were shown to be ubiquitously expressed 
during EBV latency and often make up a notable number of cellular miRNAs. Viral miRNAs comprise upwards 
of a quarter of all miRNAs in studied eBL lines such as Jijoye12. These miRNAs are a major mechanism by which 
the virus manipulates the host cells during latency13. Studies have suggested that EBV miRNAs were able to 
dampen immune surveillance of the infected host cells by down-regulating important genes in viral detection, 
such as the JAK/STAT pathway8. Moreover, EBV miRNAs in a few cancers have been associated with angiogenesis 
and more aggressive tumors14–17. Specific EBV miRNAs have also been linked to poor prognosis in patient out-
comes. For example miR-Bart20-5p expression was associated with decreased survival in gastric cancer tumors15. 
Furthermore, EBV miRNA transcripts were also reported to be an independent prognostic indicator for patients 
diagnosed with advanced NPC15,18. More intriguing a recent study of approximately 2300 individuals from a more 
limited set of 13 cancers from TCGA study showed the presence of any EBV miRNAs was correlated with poor 
survival in low stage malignancies16.
Here, we aimed to systematically ascertain and quantify the presence of EBV within cancer types by screening 
for viral miRNA. To do so, we developed a computational framework for EBV miRNA detection and quantifica-
tion using publicly available datasets. We then categorized viral miRNA expression levels as a means to identify 
EBV-infected tumors or loss of immune control over EBV in the tumor microenvironment and apply this metric 
in patient survival analyses finding an association with poor prognosis in adult AML, which we subsequently 
investigate further.
Results
EBV detection and classification across cancers. To better assess the presence of EBV across a spec-
trum of cancers, we examined 27 different tumor types for the presence of 44 EBV miRNAs as well as smaller 
fragments of other viral non-coding RNAs (ncRNAs) including EBERs (Methods and Supplementary Fig. S1). 
We included miRNA-seq datasets encompassing a total of 8,955 individual tumors with an average of 336 samples 
per cancer (range 19–592). The samples were predominantly drawn from the TCGA and TARGET datasets, and 
we also included 19 EBV-associated eBL tumors that our group has previously sequenced (Methods, Table 1)14. 
Tumor specimens, which might include other host cells within the tumor microenvironment, had marked differ-
ences in EBV miRNA abundance (Fig. 1). EBV presence was not solely correlated with past associations of viral 
positive tumor cells. Overall, samples with EBV miRNAs and EBERs ≥ 1 copies per million (CPMs) were present 
in 27% (n = 2418) of all samples. EBV positive samples ≥ 10 CPMs total viral miRNAs and EBERs were detected 
in 10.1% (n = 903) of all tumor samples with individual cancers ranging from 1% to 89% viral miRNA load. 
However, this did not represent necessarily infected tumor cells, given that the vast majority of adults who were 
latently infected with EBV were thereby harboring virus at low levels in latently infected B cells. Thus, detecting 
low levels of EBV was not unexpected, particularly given that up to 25% of an infected cells’ miRNA could be of 
viral rather than human origin14. We therefore aimed to set rational thresholds that would be indicative of tumor 
cell infection as well as levels that might define uncontrolled EBV-infected non-tumor cells within the tumor 
microenvironment.
For this, we categorized three general groupings. We first defined a subset of cancers with abundant or 
high-level EBV miRNA expression at ≥10,000 CPM. These were likely a result of EBV containing tumors and 
miRNA expression within the tumor cells and represented 0.52% of the total samples examined. This category 
captured all cancers known to harbor EBV and at frequencies consistent with previous reports based on EBER 
positivity: 63% for eBL, 7.5% for stomach cancer, and 2.2% for diffuse large B cell lymphoma. These samples 
appeared by-and-large to express the full complement of viral miRNAs. While concordant with EBV positive 
rates as defined by EBERs staining, these levels were likely conservative. For eBL, positivity was lower than deter-
mined based on other metrics2. As no samples were categorized as high-level outside of tumors with previous 
EBV-associations, our results were consistent with other tumor types not directly harboring the virus, except for 
the possibility of rare sporadic cases or a small proportion of tumor cells.
The second level of expression we categorized as medium (10–10,000 CPM), which could be the consequence 
of a low fraction of infected tumor cells, lower expression within tumor cells, or benign B cells harboring the virus 
(circulating or tumor-infiltrating lymphocytes) reflective of poor immune control over the infection13. Overall, 
10% (n = 898) of our samples fell within this category. In general, this correlated with tumors known to have 
significant lymphoid infiltrates such as gastrointestinal cancers. Interestingly, 68% (n = 321) of gastric cancers fall 
within the medium category and these appear to be distinct from the samples with high EBV miRNA abundances. 
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Cancer Total Negative Positive Medium EBV Levels High EBV Levels
Acute Myeloid Leukemia, Adult 103 88 (85%) 15 (15%) 15 (15%) 0
Acute Myeloid Leukemia, Pediatric 263 247 (94%) 16 (6%) 16 (6%) 0
Adrenal Gland Cancer 95 94 (99%) 1 (1%) 1 (1%) 0
Bladder Carcinoma 456 412 (9%) 44 (1%) 44 (10%) 0
Brain Cancer 501 491 (98%) 10 (2%) 10 (2%) 0
Breast Cancer 479 469 (98%) 10 (2%) 10 (2%) 0
Cervical Cancer 307 292 (95%) 15 (5%) 15 (5%) 0
Colon Adenocarcinoma 462 368 (8%) 94 (2%) 94 (2%) 0
Diffuse Large B Cell Lymphoma 45 30 (67%) 15 (33%) 14 (31%) 1 (2%)
Endemic Burkitt Lymphoma 19 2 (11%) 17 (89%) 5 (26%) 12 (63%)
Esophageal Cancer 186 135 (73%) 51 (27%) 49 (26%) 2 (1%)
Head and Neck Cancer 528 457 (87%) 71 (13%) 71 (13%) 0
Kidney Papillary Cell Carcinoma 291 289 (99%) 2 (1%) 2 (1%) 0
Kidney Renal Clear Cell Carcinoma 537 532 (99%) 5 (1%) 5 (1%) 0
Liver Carcinoma 377 366 (97%) 11 (3%) 12 (3%) 0
Lung Adenocarcinoma 522 487 (93%) 35 (6%) 35 (6%) 0
Lung Squamous Carcinoma 504 442 (88%) 62 (12%) 63 (12%) 0
Ovarian Cancer 592 570 (96%) 22 (4%) 22 (4%) 0
Prostate Cancer 499 496 (99%) 3 (1%) 3 (1%) 0
Rectal Adenocarcinoma 161 120 (75%) 41 (33%) 40 (24%) 0
Sarcoma 124 121 (98%) 3 (1%) 3 (2%) 0
Stomach Adenocarcinoma 456 105 (23%) 351 (76%) 317 (68.5%) 34 (7.5%)
Testicular Cancer 134 130 (97%) 4 (2%) 4 (3%) 0
Thymoma 124 122 (98%) 2 (2%) 2 (1.6%) 0
Thyroid Cancer 503 501 (99.5%) 2 (0%) 2 (0.5%) 0
Uterus Cancer 548 536 (98%) 12 (2%) 12 (2%) 0
Wilms Tumor 139 139 (100%) 0 0 0
Table 1. EBV miRNA levels for each cancer type. Positive samples are samples with ≥10 counts per million 
(CPM) of viral miRNA and EBER expression. Negative samples are those with ≤10 CPM of viral miRNA and 
EBERs levels. Green lines signify cancers samples previously associated with Epstein Barr Virus (EBV). The first 
number on each cell of “number of samples with medium/high EBV level”, and the second number in the 
parenthesis represents “the percent of the latter samples”.
Figure 1. EBV miRNA quantitative expression across cancer spectrum. In general, the total viral miRNA load 
at the highest levels (≥104 CPM) were observed only in tumors previously associated with harboring the virus 
(pink/purple), which correlate with reported proportions of viral positive tumors in the literature. Previously 
unassociated tumors (green) posses viral miRNA levels only at intermediate (101–104 CPM) or low (<101 CPM) 
levels. Gastric tumors were interesting in that a majority (69.5%) fall within in the medium category suggesting 
an association with EBV beyond simple viral infection of the tumor in the 10% at high levels. The y-axis 
represents log10 counts of viral miRNA per total human and viral miRNA aligned to their respective genomes. 
The dashed lines separate the defined categories of viral miRNAs based on designated expression levels and and 
diamond lines denote median expression levels.
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Finally, 88% (n = 7863) of samples screened had low to absent EBV miRNA expression levels (<10 CPM). Such 
low levels likely represent EBV-negative tumors and individuals with well-controlled infections. This threshold 
of 10 CPM was consistent with our knowledge of tumors lacking an association with EBV and those minimally 
associated tumor infiltrating lymphocytes. This included tumors such as Wilms tumor, adrenal gland carcinoma 
where none of those we examined surpassed the 10 CPM cutoff. This level conservatively suggested that less than 
1 in 100,000 cells were infected with EBV presuming viral miRNAs were 25% of total cellular content19,20.
pattern of miRnAs and eBeRs across cancer subtypes. We sought to investigate the pattern of small 
RNA expression across cancers and performed principal component analysis (PCA) (Fig. 2A). We examined 
only samples with significant EBV content (≥10 CPM). The first three principal components (PCs) accounted 
for 90% of the variation (Fig. 2A and Supplementary Fig. S2). Most samples fell on a continuum defined by PC1 
which appeared to correlate with the absolute amount of expression. PC1 and PC2 defined two distinct clusters 
of B cell derived (pink/purple) and epithelial (green) apart from the majority of sample. The eBL and diffuse 
large B cell lymphoma fell into what we defined as the B cell cluster while high level gastric and esophageal 
cancers fell in the epithelial cell cluster. We also compared the expression from these two clusters more closely 
revealing distinct expression patterns (Fig. 2B). ebv-mir-bart8-5p, ebv-mir-bart17-3p, and ebv-mir-bart11-5p 
were expressed in both B cells and epithelial cells. For highly expressed miRNAs (>1000 CPM) (Fig. 2C), 
we found ebv-mir-bart8-3p, ebv-mir-bart7-3p, ebv-mir-bart22, ebv-mir-bart10-3p, ebv-mir-bart6-3p and 
ebv-mir-bart9-3p are increased in epithelial cluster. Highly-expressed EBV miRNAs increased in the B cell clus-
ter were ebv-mir-bart11-3p, ebv-mir-bart-17-5p and ebv-mir-bart19-3p, and ebv-mir-bart19-5p.ic. Given these 
significant differences are based on cell type, these may provide useful markers for better understanding the cell 
type of origin within tumors or provide specific biomarkers.
Figure 2. PCA on relative expression of EBV miRNA of EBV positive samples. (A) PCA1–2 represented 72% 
of the variance across samples. The pink circle included tumor samples with B cell origins (PC2). The green 
circle encompassed tumor samples with epithelial origins (PC1). (B) Heatmap of hierarchical clustering of the 
samples circled in (A) in terms of patterns of viral miRNA expression in total fraction of viral reads per million 
(FTVRM). (C) Bar plots represented cell type specific patterns of viral miRNAs expression across samples (from 
red circle and purple circled samples in A). Each bar represented average fraction of EBV miRNA expression. 
Note only P-value significant EBV miRNAs (P < 0.05 wilcoxon rank test with bonferroni correction) were 
shown with above average fraction of 0.03 per miRNAs across samples, bar plot of all viral miRNAs can be 
found in Supplementary Fig. 2C.
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Survival outcome for eBV positive tumor samples across cancer subtypes. To address our central 
question regarding whether EBV impacts the clinical outcome of cancer patients, we used our more sensitive 
measure of total EBV miRNA in our survival analysis. We examined patient survival across tumor types hypoth-
esizing that levels above a normally controlled infection could be associated with clinical outcomes. Using both 
the Kaplan-Meier test and general linear model (GLM), we tested EBV positivity, defined by combining high 
and medium levels, as ≥10 CPM in comparison to negative tumors, defined as to low or absent expression (<10 
CPM). Based on this categorization, only one tumor type, adults with acute myeloid leukemia (AML) demon-
strated significantly different 1000 day survival rates when controlling for multiple testing. EBV positive adult 
AML patients had significantly worse survival rates relative to their EBV negative counterparts at 1000 days 
(P = 0.00013 Kaplan Meier, Bonferroni-corrected P = 0.02, Fig. 3A, Supplementary Table S1). For EBV positive 
patients survival for an adult AML diagnosis was only 6% (1 out of 15 EBV positive tumors) compared to 43% 
(31 out of 72) for patients with EBV negative tumors, with an odds ratio of 0.095 (0.012–0.76). This survival 
difference was robust even with a lower threshold (Supplementary Table S1). Moreover, patients who died had 
significantly higher EBV miRNA levels than those who survived (Fig. 3B). Interestingly, this association was 
not observed for pediatric AML where there was no difference between EBV status and survival (56% for EBV 
positive (n = 9/16) and 59% for EBV negative (n = 148/247), Kaplan Meier P = 0.74). The survival disadvantage 
in adults was robust even after controlling for sex and age (GLM P = 0.0439). EBV infection status alone was not 
significantly associated with other clinical and molecular risk factors, including AML French, American and 
British classification (FAB), based on univariate analysis using the 84 of 103 AML samples with detailed clinical 
annotation (Supplementary Table S2). Together, our findings suggest that EBV miRNA levels might represent an 
independent biomarker associated with poor prognosis in adult AML.
prognostic risk model for adult AML incorporating eBV miRnA. To examine the potential prog-
nostic power of EBV miRNA status for survival in conjunction with other known risk factors, we performed 
multivariate Cox regression analysis (Table 2). Our multivariate analysis detected other previously associated 
factors including age, eosinophil levels, inversion 16 and trisomy 21 significantly associated with risk in adult 
AML tumors. EBV was the strongest prognostic predictor among all features. We also examined interactions 
between risk factors, such as age and percent eosinophils, to detect potential confounding. Our results indi-
cated <1% confounding suggesting that EBV miRNA status was independently associated with survival in adult 
AML (Table 2). We next tested the prognostic power using a Cox model incorporating the above variables and 
previous risk factors along with EBV miRNA status. A machine learning algorithm was used to determine the 
significance of the addition of EBV miRNA positivity in the prognosis of AML patients. We again examined 
interactions and removed any highly correlated factors21 (Supplementary Fig. S3). Using bootstrapping and 
leave-one-out cross validation (LOOCV), we then tested the prognostic power on withheld samples from our 
Cox-model of survival incorporating EBV status as well as other significant univariate predictors (percent eosin-
ophils within tumors, Trisomy 21, Inversion 16, and Age). The discriminatory power represented by the area 
under the curve (AUC) improved with the inclusion of EBV miRNA status as a variable (0.62 to 0.72 respectively) 
(Fig. 3C, Supplementary Table S3). To better assess the significance we permuted EBV status which showed that 
our observation of the AUC was significant (P = 0.02).
As an alternative model, akin to previous post remission treatment (PRT)22, we used the cytogenetic classifi-
cation instead of the individual key cytogenetic aberrations. Although we were not able to replicate the previous 
Figure 3. Survival analysis and prognostic model for EBV status in adult AML. (A) Kaplan-Meier curve 
compared the survival of EBV positive (blue) versus negative (red) AML patients in 1000 day survival analysis 
which significantly differed (P < 0.00013). (B) The difference in total miRNA EBV levels was remarkable when 
comparing patients who survived or died with only one survivor greater than 101 CPM (wilcoxon rank test 
P-value = 9.3 × 10−07). (C) Area under the curve (AUC) based on cutoffs for the multivariate Cox prediction 
model using bootstrapped cross validation when EBV was modeled as a feature along with age, percent 
eosinophils, and number Trisomy 21 inversion 16 mutations.
6Scientific RepoRtS |         (2019) 9:20321  | https://doi.org/10.1038/s41598-019-56472-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
PRT score with available data, due to lacking a measure of blast numbers within the TCGA dataset, we were able 
to demonstrate that EBV miRNA status incorporation improved the model: AUC 0.59 to 0.70 for poor and AUC 
0.59 to 0.69 for intermediate outcome category (Supplementary Fig. S4, Supplementary Table S3). Overall, our 
modeling suggested that EBV miRNA levels have the potential to serve as a clinically actionable prognostic bio-
marker for adult AML.
Host transcriptome expression difference between EBV positive and negative adult AML tumor 
samples. We next sought to explore potential biological differences that might underlie increased levels of 
EBV miRNA at diagnosis and help explain the association with decreased survival. We first performed differ-
ential transcriptome expression analysis on host mRNA expression in relation to EBV miRNA status (12 adult 
AML samples at EBV miRNA and EBERs 1000 > CPM ≥ 10 (medium EBV group), and 14 samples at CPM = 0 
(no EBV reads), respectively) with available RNA-seq data. We detected 18 differentially expressed human genes 
(q ≤ 10%) after we removed genes that were also significantly differentially expressed when survivors and non-
survivors were compared in these samples (Fig. 4). Host genes previously known to be upregulated during EBV 
infection of B cells were also upregulated in our dataset such as HLA-DQ and HLA-DRB23. A collection of genes 
associated with inflammation, interferon I and II activity in addition to neutrophil and macrophage deregula-
tors were also differentially expressed between EBV positive and negative samples. These genes include MX1, 
ANAX2P2, DEFA1, NCF1C, CLC, and SPIB24–27. GO biological enrichment analysis found enrichments includ-
ing an increase in reactive oxygen species and metabolic cell processing pathways when the tumor samples were 
classified as EBV positive (ROS metabolic process). The latter process has been well studied in terms of its asso-
ciation with inflammation and increase in cancer cells28. The host genes involved in this process were HBG1, 
HBG2 and NCF1C. GO cellular component enrichment shows higher than average expression of MHC Class II 
proteins complex involvement in addition to increase in cytoplasmic vesicle formation. Reactome pathway anal-
ysis showed enrichment in immune system signaling such as interferon signaling, alpha defensins and cytokine 
signaling (FDR corrected P value ≤ 0.1) (Supplementary Table S5).
No viral mRNAs were observed to be relatively enriched, which was not unexpected given the normally low 
expression level of EBV poly A transcripts and the reduced or silenced viral gene expression during latency. In 
fact, we could barely detect viral mRNA reads (<7 reads per kilobase per million (RPKM) per gene) in 13 out of 
15 EBV miRNA positive AML samples (Supplementary Fig. S5) with the greatest combined viral mRNA expres-
sion of 14 RPKM. The viral genes most evident were A73/RPMS1 and EBNA1, consistent with a latency I pattern 
of infection while EBV lytic genes including BALF4 and BNLF2A were minimially expressed. Two AML samples’ 
Feature Coefficient Pr(>|z|)
Age 2.22E−02 0.08207
EBV 1.32E + 00 0.0045
Eosinophil Percent 2.52E − 01 0.00457
Lymphocyte Percent 3.86E − 05 0.99648
Myelocyte Percent 3.96E − 02 0.55609
Neutrophil Percent −6.65E − 03 0.62223
Monocyte Percent 2.09E − 03 0.95954
Translocation 8–21 −3.28E − 01 0.64948
Inversion 16 −2.34E + 00 0.03145
Translocation 8 9.62E − 02 0.87208
del(5q)/5d- 1.01E + 00 0.12995
del(7q)/7d- 7.36E − 01 0.25181
Translocation 9–22 −1.38E + 01 0.98869
Trisomy 21 2.75E + 00 0.00411
Translocation 4–11 −2.02E + 00 0.14934
Translocation 9–11 1.89E + 00 0.15012
Translocation 15–17 −1.39E + 00 0.16105
idh1_r140 1.20E − 02 0.98419
idh1_r132 −2.22E + 00 0.0387
NPMC 4.37E − 01 0.37311
FLT3 −5.90E − 02 0.88937
Gender −4.17E − 01 0.30107
Table 2. Multivariable Cox regression for AML samples. The coefficient represents the impact of features. 
Pr(>|z|) defines the statistical significance. |z| is the absolute value of the Wald statistics. It represents if the 
feature coefficient is statistically different from zero. Each translocation is from a chromosome to another, for 
example Translocation 8–21 is a translocation between chromosomes 8 and 21. The cytogenetic deletion on 
various sites and sizes on chromosome 7, and 5 are represented by del. Mutations on the IDH1 gene on arginine 
amino acid (r) on various sites (132,140) observed in adult AML tumors. FLT3 mutation are consistently 
observed in forms of insertion, deletions and missense and intronic variants and reported as part of patient 
clinical information.
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mRNA expression was constrained to two latency III genes, i.e. EBNA-2 and EBNA-LP although we could detect a 
mosaic of lytic genes expressed in the rest of the AML samples. The latter finding was consistent with our miRNA 
data which implied viral detection by the host immune system and upregulation of the host defense mechanisms 
during episodic lytic reactivation.
Discussion
Ninety seven percent of the world’s adult population is latently infected with EBV yet it is not fully understood 
why certain individuals develop EBV-associated cancers. Here we used ubiquitously-expressed EBV miRNAs as 
a more sensitive metric, not only to detect EBV but also to quantify the virus residing within the tumors and/or 
the tumor microenvironment. Characterizing a wide variety of cancers for EBV miRNA levels, we found a novel 
association with elevated viral miRNA levels and poor survival in adult AML patients that likely represents an 
independent prognostic predictor. As EBV is a prevalent chronic infection we set reasonable cutoffs to differ-
entiate tumors bearing the virus (high levels), in contrast to uncontrolled infection of normal and/or a small 
proportion of tumor cells (medium levels), and well-controlled or uninfected individuals (low or absent levels). 
In general, our results were consistent in identifying EBV within tumors with previously defined associations. 
Interestingly, miRNA expression found at medium levels in a wider variety of cancers suggest that EBV might be 
poorly controlled within the patient or within the tumor microenvironment. In support of this premise, the latter 
also correlated with tumor types known to contain higher proportions of tumor infiltrating lymphocytes7,10,29.
Given our novel association between EBV miRNA levels and adult AML survival, we focused on further 
exploring its potential as a prognostic biomarker as well as exploring its role as a surrogate for immune dysregula-
tion. Using a multivariate Cox model EBV miRNA status appeared to be an independent biomarker for survival, 
further improving outcome predictions. We examined this both with de novo modeling as well as modeling based 
on the previously validated PRT models. While this association and its ramifications require additional validation 
in an independent cohort, it would be interesting to determine whether other measures of EBV, such as peripheral 
viral miRNA loads or peripheral miRNAs, might serve as surrogates of tumor burden, immune competence or 
able to provide longitudinal information during the course of treatment and while in remission.
To explore the biology of this association, we examined expression differences between patients with medium 
level viral miRNA expression compared to those with no evidence of EBV. We found that increased expression 
of innate inflammation mediators correlated with miRNA EBV levels. While this finding could be affected by 
confounding given AML represents an aberrant leukocyte precursor, one of the most interesting genes showing 
expression differences was MX1. MX1 gene has been linked, not only to EBV, but to progression of acute lympho-
cytic leukemia by acting as a binding partner of LMP1 viral gene in EBV positive samples in acute lymphocytic 
leukemia but as tumor inducing factor in myeloid leukemia30. MX1 has been shown to be involved in interferon 
alpha and interferon gamma expression and has been associated with reactivation of EBV infection in gastric 
cancer and lymphomas31.
Taken together, we proposed a model whereby EBV miRNA levels in adult AML patients reflect the immune 
status of the patient. Immune alterations during cancer could be general (and proceed tumorigenesis) or might be 
specific to the local tumor microenvironment. This would be consistent with the lack of association in pediatric 
AML, where increased EBV may due to primary infection or reactivation directly rather than immune dysfunc-
tion. Further exploration examining EBV from peripheral blood as well as isolated tumors and tumor infiltrating 
lymphocytes (using single cell RNA-seq) could help answer such questions. Our lack of association in pediatric 
Figure 4. Differential mRNA transcriptome gene expression analysis comparing AML cases with medium and 
no EBV miRNA expression. Volcano plot showed differential expression between samples above 10 CPMs of 
EBV reads (n = 12) and those lacking viral miRNA and EBER expression (and n = 14). Genes increasing in EBV 
positive AML show a fold change increase (right side of the volcano plot) and those decreasing show a reduction 
in fold change (to the left side of the volcano plot). Genes which were colored orange posses q-values (false 
discovery rate) below 0.1 (Supplementary Table S4).
8Scientific RepoRtS |         (2019) 9:20321  | https://doi.org/10.1038/s41598-019-56472-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
AML might be in part due in part to the relative lack of children being infected with EBV compared to adults, but 
we hypothesize that EBV in children may represent primary infections or reactivations that are unassociated with 
decline in immunity.
We also found that expression patterns of viral miRNAs are differentiated based on tumor cell type, broadly 
separating them into B cell derived tumors and those of epithelial origin (Fig. 2C). Of the highly expressed EBV 
miRNAs we found differential expression where ebv-mir-bart11-3p, ebv-mir-bart-17-5p, ebv-mir-bart19-3p, 
and ebv-mir-bart19-5p were increased in B cell tumors; whereas ebv-mir-bart8-3p, ebv-mir-bart-7-3p, 
ebv-mir-bart22, and ebv-mir-bart10-3p were increased in epithelial tumors. These findings are consistent with 
previous studies32–34. For instance, ebv-mir-bart19-5p has been reported to downregulate LMP1 expression35 
which is not expressed in EBV latency I malignancies (that do not express LMP1) compared to epithelial tumors 
that have a latency II viral gene expression pattern (which by definition expresses LMP1). Also, ebv-mir-bart22 
has been observed to suppress LMP2 expression and protect the infected cells from immune recognition35. This 
viral miRNA was higher in EBV latency II epithelial gastric tumors, which was consistent with the normal cell 
type latency pattern36. It will be interesting to further investigate EBV miRNA signatures in terms of tumor 
cell type of origin and determine if viral self-regulation mechanisms also promote tumorigenesis (ie cell sur-
vival). It will also be interesting to see if B cell versus epithelial signatures can be further correlated with EBV 
sub-localization within the tumor microenvironment. While speculative, given we did not find pronounced sig-
natures for B cell tumors with medium expression, further investigation into the roles of shared EBV miRNAs 
should provide insight into the mechanisms of EBV tumorigenesis, regardless of malignant cell type.
Overall, our findings of prevalent miRNAs, elevated above levels observed in controlled infection, provide 
evidence that EBV may represent an important prognostic biomarker and can provide important insight into 
host immune status associated with survival. Further validation, as well as extending these findings to peripheral 
markers and determining whether monitoring EBV miRNA levels during the course of disease may further pre-
dict adverse long-term outcomes, are warranted. Most importantly our results indicate that the investigation of 
EBV both biologically and as a biomarker should not simply be limited to instances where cancer cells contain 
the virus.
Materials and Methods
tumor sample selection and analysis. Tumor miRNA sequencing (miRNA-seq) and associated clin-
ical data was obtained from The Cancer Genome Atlas (TCGA) (https://cghub.ucsc.edu) and Therapeutically 
Applicable Research to Generate Effective Treatments (TARGET)(https://ocg.cancer.gov/programs/target) pro-
jects through dbGaP (Project #13089) and combined with miRNA and RNA sequencing of eBL from Western 
Kenya (dbGaP accession number phs001282.v2.p1)14. For each tumor type up to 592 miRNA tumor samples were 
chosen, preferentially selecting those with available messenger RNA sequencing (mRNA-seq)37. Overall, a total of 
8,955 miRNA samples were analyzed. All adult AML were collected as primary tumors and no information about 
future chemotherapy regimen was provided in the clinical metadata for these samples. Nasopharyngeal cancer 
(NPC) samples were not added to this study due to the absence of EBV reads in the available public miRNA seq 
datasets.
ethical approval and sample collection. Fine-needle aspirates (FNA) were obtained between 2009 and 
2012 at the time of diagnosis and prior to commencing chemotherapy at Jaramogi Oginga Odinga Teaching 
and Referral Hospital (JOOTRH), the regional referral hospital for pediatric cancer located in western Kenya. 
Giemsa/May-Grünwald was performed on the FNAs for morphologic diagnosis by microscopy. All experiments 
were performed in accordance with relevant guidelines and regulations. Written informed consent was obtained 
from all subjects or, if subjects are under 18, from a parent and/or legal guardian before enrollment. Ethical 
approval was obtained from the Institutional Review Board at the University of Massachusetts Medical School 
(UMMS) and the Scientific and Ethics Review Unit at the Kenya Medical Research Institute.
Detection and quantification of EBV miRNAs. The miRNA binary alignment map (bam) reads were 
extracted and adapter sequences removed using Cutadapt-1.9.1. The trimmed reads were then aligned simul-
taneously to the human (hg19) and EBV reference genome (NC_007605) to detect best placements using 
Burrows-Wheeler Aligner (bwa-0.7.17). This alignment was done with recommended miRNA-aligning param-
eters including zero mismatch for the seed of 8 base pairs. This protocol was optimised for miRNA-seq but addi-
tionally detected other viral ncRNAs including EBERs38–40. To remove human contamination including cross 
mapping human miRNAs, only miRNA alignments that best mapped to the EBV genome were retained. We 
allowed for multiple best placements within the EBV genome so as not to exclude miRNAs arising from the repet-
itive regions. The method allowed for one base differences relative to the reference genome. Specific miRNAs and 
small EBER fragments were then quantified based on their defined genomic locations (miRBase version 22) as 
copies per million (CPM) using bedtools and in-house parsing scripts41–43. We did not detect significant expres-
sion of novel miRNAs outside miRBase defined locations. Total counts per million (CPM) values of all samples 
are now added as (Supplementary Table S6) for de-identified samples.
Survival analysis. Survival analyses were performed in R including Kaplan-Meier survival analysis (using 
survival package), as well as univariate and multivariate logistic regression. Exclusion of potential confounders 
was determined by measuring the association before and after adjusting for a potential confounding variable and 
subsequently excluding those variables with greater than 10% change of effect44.
Hazard analysis using cox regression with bootstrapping and cross validation. In order to assess 
the risk associated with the hazard of EBV positivity in our dataset, we used the standard Cox multivariable risk 
assessment method to regress the parameters of interest jointly. The R scripts for Cox-regression, bootstrapping 
9Scientific RepoRtS |         (2019) 9:20321  | https://doi.org/10.1038/s41598-019-56472-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
and risk prediction using cross validation could be accessed through GitHub (https://github.com/bailey-lab/
EBV_Cox-Regression.git) utilizing the censboot and Cox-regression packages using the general multivariate esti-
mator g(x,ß) = exß in R. To test prognostic power, we used a multivariate 1000 bootstrapped leave-one-out cross 
validated (LOOCV) model to predict the risk associated with being EBV positive in concordance with patient 
survival, whereby we estimated the risk of EBV positivity of our parameters45,46. Area under the curve (AUC) for 
the performance of our prediction model was estimated at various thresholds to ascertain the risk associated with 
EBV for every predicted sample and permutation was used to determine the significance of AUC curves.
Differential expression analysis. Differential expression analysis comparing EBV positive versus EBV 
negative samples was performed using the Tuxedo Tools (cufflinks, and cuffmerge and cuffdiff). Gene ontology 
(GO) enrichment analysis was done using python in house scripts utilizing Panther database47.
Data was visualized using a variety of R packages including libraries ggplot2, qqman, prcomp, dplyr, Tydiverse 
and pheatmap. All statistical analyses were done using validated R, and python functions and scripts.
Data availability
No data was generated during the current study. Tumor samples analysed for this study were downloaded from 
The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Treatments 
(TARGET)projects through dbGaP (Project #13089) and combined with miRNA and RNA sequencing of eBL 
from Western Kenya (dbGaP accession number phs001282.v2.p1).
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